The US Food and Drug Administration (FDA) has approved Andexxa (coagulation factor Xa [recombinant] inactivated-zhzo) to reverse the anticoagulation effects of factor Xa inhibitors when needed due to ...
Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...
Despite considerable reductions in cardiovascular events in patients with an acute coronary syndrome (ACS) receiving dual antiplatelet therapy (DAPT), substantial residual risk persists. This unmet ...
If you live with atrial fibrillation (sometimes called AF or AFib), a type of irregular heartbeat, you probably take a blood thinner to reduce your risk of stroke and blood clots. Research shows that ...
SAN FRANCISCO, CA – A phase 3 study designed to test an antidote to the factor Xa inhibitor class of novel anticoagulants met its primary efficacy end point, according to an announcement from Portola ...
ORLANDO, FL—A new interim analysis of the ongoing ANNEXA-4 study evaluating andexanet alfa (AndexXa; Portola Pharmaceuticals) affirms that the drug rapidly reverses the anticoagulant effects of the ...
Tissue factor initiates the extrinsic coagulation pathway by activating coagulation factor X to factor Xa, and factor V is a cofactor for the prothrombin activation by factor Xa. As factor Xa is known ...
Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was ...
Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume but was associated with ...
New research by a team led by researchers from the Department of Cardiovascular Medicine at Tokyo Medical and Dental University (TMDU); and the Department of Cardiovascular Medicine at Tokyo Kyosai ...
New research sheds light on the mechanism by which Rivaroxaban suppresses factor Xa and successfully attenuates atherosclerosis. New research by a team led by researchers from the Department of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results